Loading...
Publication
Epigalocatequina-3-galato (EGCG) na síndrome de Down
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| PPG_31367 | 3.02 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
A epigalocatequina-3-galato (EGCG) é um dos polifenóis que compõem o chá verde, obtido da Camellia sinensis, reconhecido como possuindo imensos benefícios para a saúde humana, nomeadamente na prevenção de vários tipos de doenças, como o cancro, doenças cardiovasculares, neurodegenerativas, renais e hepáticas. Dentro do grupo dos polifenóis, a EGCG é uma das catequinas responsáveis pela ação antioxidante, antiinflamatória, antimicrobiana, anticarcinogénica, antitumoral, antiangiogénica, antihipertensiva e reparadora tecidular do chá verde.
A Síndrome de Down é uma alteração específica no genoma causada pela ocorrência de trissomia do cromossoma 21. O fenótipo dos indivíduos portadores desta síndrome é bem característico, diferenciando-se em relação a outras síndromes. Uma cópia extra do gene DYRK1A presente no cromossoma 21 resulta numa dificuldade de aprendizagem, défice cognitivo moderado a acentuado e algumas alterações motoras em pessoas portadoras desta síndrome, estando também presente em algumas doenças neurodegenerativas, como a doença de Alzheimer. Os resultados de vários estudos analisados demonstraram que a EGCG presente em grande quantidade nas folhas de chá verde atua seletivamente e de forma segura ao nível da proteína codificada por este gene, inibindo-a e proporcionando um desenvolvimento cerebral normal.
Efetivamente, estudos feitos em animais e humanos demonstraram que a EGCG é capaz de diminuir a atividade da proteína DYRK1A, controlar o envelhecimento celular precoce, minimizar a disfunção mitocondrial e diminuir o stress oxidativo, promovendo uma melhoria da função cognitiva. Assim, de acordo com a literatura, este polifenol em particular poderá contribuir para um aumento da qualidade de vida das pessoas portadoras de Síndrome de Down. No entanto, é ainda necessário aprofundar a investigação para se
perceber quais as doses máximas recomendadas, bem como a idade de início da suplementação com EGCG, de modo a que seja eficaz e com efeitos duradouros.
Epigallocatechin-3-gallate (EGCG) is one of the polyphenols present in green tea, obtained from Camellia sinensis, recognized for its several benefits to human health, namely in the prevention of diverse types of diseases, such as cancer, cardiovascular diseases, neurodegenerative diseases, renal and liver diseases. Within the polyphenols group, EGCG is one of the catechins responsible for the antioxidant, anti-inflammatory, antimicrobial, anticarcinogenic, antitumoral, antiangiogenic, antihypertensive role and for the tissue repair action of green tea. Down Syndrome is a specific alteration in the genome, which is caused by the presence of trisomy of chromosome 21. The phenotype of individuals with this syndrome is quite characteristic, differentiating it from other syndrome types. An extra copy of the DYRK1A gene present in chromosome 21 results in learning difficulties, a cognitive deficit from moderate to severe, and some motor alterations. It is also present in some neurodegenerative diseases, such as Alzheimer's disease. Results of several studies have shown that EGCG is found in large quantities in green tea leaves and acts selectively and safely on the protein codified by this gene, by inhibiting it, which allows a normal development of the brain. Indeed, studies carried out in animals and humans demonstrated that EGCG is able to decrease DYRK1A protein activity, control premature cell aging, minimize mitochondrial disfunction and reduce oxidative stress, promoting an improvement of cognitive function. Thus, according to the literature, this polyphenol in particular could contribute to an increase of the quality of life of people with Down Syndrome. However, further investigation is necessary to unveil the recommended maximum doses, as well as, the best age to start EGCG supplementation, so that it could be effective and with lasting effects.
Epigallocatechin-3-gallate (EGCG) is one of the polyphenols present in green tea, obtained from Camellia sinensis, recognized for its several benefits to human health, namely in the prevention of diverse types of diseases, such as cancer, cardiovascular diseases, neurodegenerative diseases, renal and liver diseases. Within the polyphenols group, EGCG is one of the catechins responsible for the antioxidant, anti-inflammatory, antimicrobial, anticarcinogenic, antitumoral, antiangiogenic, antihypertensive role and for the tissue repair action of green tea. Down Syndrome is a specific alteration in the genome, which is caused by the presence of trisomy of chromosome 21. The phenotype of individuals with this syndrome is quite characteristic, differentiating it from other syndrome types. An extra copy of the DYRK1A gene present in chromosome 21 results in learning difficulties, a cognitive deficit from moderate to severe, and some motor alterations. It is also present in some neurodegenerative diseases, such as Alzheimer's disease. Results of several studies have shown that EGCG is found in large quantities in green tea leaves and acts selectively and safely on the protein codified by this gene, by inhibiting it, which allows a normal development of the brain. Indeed, studies carried out in animals and humans demonstrated that EGCG is able to decrease DYRK1A protein activity, control premature cell aging, minimize mitochondrial disfunction and reduce oxidative stress, promoting an improvement of cognitive function. Thus, according to the literature, this polyphenol in particular could contribute to an increase of the quality of life of people with Down Syndrome. However, further investigation is necessary to unveil the recommended maximum doses, as well as, the best age to start EGCG supplementation, so that it could be effective and with lasting effects.
Description
Keywords
Suplementação com EGCG Polifenol Chá verde Síndrome de Down Doenças neurodegenerativas Gene DYRK1A Food supplements with EGCG Polyphenol Green tea Down syndrome Neurodegenerative diseases DYRK1A gene